Intech Investment Management LLC Has $17.93 Million Position in Johnson & Johnson $JNJ

Key Points

• Intech Investment Management LLC reduced its holdings in Johnson & Johnson by 11.3%, owning 108,097 shares valued at approximately $17.93 million, according to a recent SEC filing.
• Several institutional investors, including Highline Wealth Partners and others, have made significant changes to their positions in Johnson & Johnson, with 69.55% of the stock now owned by institutional investors.
• Johnson & Johnson's stock currently holds a consensus rating of "Moderate Buy," with a target price of $176.29 following changes in analysts' ratings and adjustments to price targets.

Intech Investment Management LLC cut its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 108,097 shares of the company's stock after selling 13,727 shares during the quarter. Intech Investment Management LLC's holdings in Johnson & Johnson were worth $17,927,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in JNJ. Highline Wealth Partners LLC increased its stake in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on JNJ shares. Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Friday, September 5th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Bank of America upped their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Finally, UBS Group raised their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Down 0.6%

Shares of Johnson & Johnson stock opened at $177.12 on Wednesday. The firm's 50 day moving average is $169.51 and its 200 day moving average is $161.02. The firm has a market capitalization of $426.57 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.